SavedAdd your journal

Journals / Archives of Current Medical Research / 2021 / Cilt: 2 - Sayı: 3

Non-Surgical Treatment Options for Peyronie’s Disease

Damla ÇINAR
Sedanur SARI
Hüseyin ALKAN
Kübra Buket AY
Enes BORCAKTEPE
Ahmet Yiğit DUYUM
Sude Sevcan FİLİKÇİ
Eren GENÇER
Çağla SENEM
Serhat SOYLU
Şeyma TUNA
Rabia TUNCER
Mehmet Emin YAZICI
Emre ALTINTAŞ
Murat GÜL
Pages
136–145
Publication Date
2021-09-22
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Food and Drug Administration) yet is clostridium collagenase histolikum, which is used in intraplaque injection, studies have shown that other methods also reduce curvature, pain, and plaque volume.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Peyronie’s disease, which occurs with the formation of a fibrous plaque in the tunica albuginea; is a disease that causes some physical problems such as bending and shortening of the penis.
📊
Key Findings & Data:There are surgical treatment methods of this disease as well as non-surgical treatment methods.
💡
Conclusion & Impact:Food and Drug Administration) yet is clostridium collagenase histolikum, which is used in intraplaque injection, studies have shown that other methods also reduce curvature, pain, and plaque volume.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Peyronie’s Disease · Non-Surgical Treatment · Plaque.

Abstract

Peyronie’s disease, which occurs with the formation of a fibrous plaque in the tunica albuginea; is a disease that causes some physical problems such as bending and shortening of the penis. There are surgical treatment methods of this disease as well as non-surgical treatment methods. Non-surgical treatment methods, which are grouped under six headings: oral treatments, topical treatments, traction and vacuum treatments, shock wave therapy, intraplate injection treatments, and experimental treatments, can be preferred in cases where the symptoms are not very advanced because they provide advantages in terms of ease of application, accessibility, and cost. Although the only non-surgical treatment method approved by the FDA (U.S. Food and Drug Administration) yet is clostridium collagenase histolikum, which is used in intraplaque injection, studies have shown that other methods also reduce curvature, pain, and plaque volume.

🔖

Cite This Article

ÇINAR, D., SARI, S., ALKAN, H., AY, K. B., BORCAKTEPE, E., DUYUM, A. Y., FİLİKÇİ, S. S., GENÇER, E., SENEM, Ç., SOYLU, S., TUNA, Ş., TUNCER, R., YAZICI, M. E., ALTINTAŞ, E., GÜL, M. (2021). Non-Surgical Treatment Options for Peyronie’s Disease. Archives of Current Medical Research, Cilt: 2 - Sayı: 3, 136–145. https://ajindex.com/articles/850286

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ory J, MacDonald L, Langille G. Noninvasive Treatment Options for Peyronie’s Disease. Sex Med Rev. 2020;8(4):603-614
  2. Paulis G, Romano G, Paulis A. Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie’s disease: a retrospective analysis of 309 cases. Res Rep Urol. 2016;8:95-103
  3. Sasso F, Gulino G, Falabella R, D’Addessi A, Sacco E, D’Onofrio A et al. Peyronie’s disease: lights and shadows. Urol Int. 2007;78(1):1-9
  4. Patel DP, Christensen MB, Hotaling JM, Pastuszak AW. A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease. World J Urol. 2020;38(2):253-261
  5. Armağan A, Soyupek S, Hoşcan B. Peyronie hastalığının medikal tedavisindeki yenilikler. Androloji Bülteni. 2004;6(17):93-98 6. Hussein AA, Alwaal A, Lue TF. All about Peyronie’s disease. Asian J Urol. 2015;2(2):70-78
  6. Hellstrom WJ, Bivalacqua TJ. Peyronie’s disease: etiology, medical, and surgical therapy. J Androl. 2000;21(3):347-54
  7. Mynderse LA, Monga M. Oral therapy for Peyronie’s disease. Int J Impot Res. 2002;14(5):340-4
  8. Akkus E, Yıldırım Ö. Peyronie hastalığı. In: Doğan HS, editor. Ürolojik Cerrahi Kitabı. İstanbul:Galenos; 2020. p. 289-319 10. Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int. 2003;91(6):522-4
  9. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model. Nitric Oxide. 2002;7(4):262-76
  10. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229-44
  11. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie’s disease. BJU Int. 2006;97(3):625-33
  12. Ozturk U, Yesil S, Goktug HN, Gucuk A, Tuygun C, Sener NC et al. Effects of sildenafil treatment on patients with Peyronie’s disease and erectile dysfunction. Ir J Med Sci. 2014;183(3):449-53
  13. Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiolo